SK bioscience Co.,Ltd. (302440.KS)
KRW 54700.0
(-5.36%)
KRW 54700.0
(-5.36%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 154.23 Billion KRW | 44.41% |
| 2022 | 124.59 Billion KRW | 29.7% |
| 2021 | 96.06 Billion KRW | 66.69% |
| 2020 | 57.63 Billion KRW | 4.66% |
| 2019 | 55.06 Billion KRW | 129.35% |
| 2018 | 24 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 39.01 Billion KRW | 0.66% |
| 2024 Q2 | 44.46 Billion KRW | 13.97% |
| 2024 Q3 | 101.26 Billion KRW | -6.79% |
| 2023 Q2 | 41.78 Billion KRW | 38.96% |
| 2023 Q1 | 30.07 Billion KRW | -36.38% |
| 2023 Q3 | -44.54 Billion KRW | -206.59% |
| 2023 Q4 | 38.75 Billion KRW | 187.0% |
| 2023 FY | 179.92 Billion KRW | 44.41% |
| 2022 FY | 124.59 Billion KRW | 29.7% |
| 2022 Q4 | 47.27 Billion KRW | 37.31% |
| 2022 Q3 | 34.42 Billion KRW | 37.96% |
| 2022 Q2 | 24.95 Billion KRW | 3.74% |
| 2022 Q1 | 24.05 Billion KRW | -15.73% |
| 2021 Q1 | 19.68 Billion KRW | -0.59% |
| 2021 FY | 96.06 Billion KRW | 66.69% |
| 2021 Q4 | 28.54 Billion KRW | -7.76% |
| 2021 Q3 | 30.94 Billion KRW | 83.29% |
| 2021 Q2 | 16.88 Billion KRW | -14.24% |
| 2020 FY | 57.63 Billion KRW | 4.66% |
| 2020 Q2 | 11.67 Billion KRW | 6.8% |
| 2020 Q3 | 15.22 Billion KRW | 30.37% |
| 2020 Q4 | 19.8 Billion KRW | 30.11% |
| 2020 Q1 | 10.93 Billion KRW | -30.33% |
| 2019 FY | 55.06 Billion KRW | 129.35% |
| 2019 Q4 | 15.69 Billion KRW | 25.7% |
| 2019 Q3 | 12.48 Billion KRW | -12.6% |
| 2019 Q2 | 14.28 Billion KRW | 13.31% |
| 2019 Q1 | 12.6 Billion KRW | -8.2% |
| 2018 Q4 | 13.73 Billion KRW | 33.61% |
| 2018 FY | 24 Billion KRW | 0.0% |
| 2018 Q3 | 10.27 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ORIENT BIO Inc. | 10.23 Billion KRW | -1407.579% |
| Green Cross Holdings Corporation | 620.02 Billion KRW | 75.125% |
| Green Cross Holdings Corporation | 424.43 Billion KRW | 63.662% |
| Pharmicell Co., Ltd. | 14 Billion KRW | -1001.317% |
| Green Cross Corporation | 424.43 Billion KRW | 63.662% |
| GeneOne Life Science, Inc. | 40.6 Billion KRW | -279.796% |
| Celltrion, Inc. | 359.46 Billion KRW | 57.095% |
| Samsung Biologics Co.,Ltd. | 638.51 Billion KRW | 75.846% |
| SK Biopharmaceuticals Co., Ltd. | 358.33 Billion KRW | 56.959% |
| Prestige BioPharma Limited | 63.47 Billion KRW | -142.99% |